Insmed (LTS:0JAV) Current Deferred Taxes Liabilities: $0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0JAV Insmed Inc LTS:0JAV
57 GF Score
Price $125.81
GF Value $211.50
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Insmed Current Deferred Taxes Liabilities?

Insmed LTS:0JAV +0.03% 57 Current Deferred Taxes Liabilities is $0 Mil as of Jun. 2026. GuruFocus rates LTS:0JAV with a GF Score™ of 57/100 and a GF Value™ of $211.50 (Possible Value Trap). The stock has 4 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Insmed's current deferred tax liabilities for the quarter that ended in Jun. 2026 was $0 Mil.

Insmed Current Deferred Taxes Liabilities Related Terms

Insmed Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Insmed's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insmed Current Deferred Taxes Liabilities Chart

Insmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Insmed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0JAV
57GF Score
Insmed Inc LTS:0JAV
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of $0 Mil mean?
Insmed (LTS:0JAV) has a Current Deferred Taxes Liabilities of $0 Mil as of Jun. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Insmed and its competitors.
Is Insmed's Current Deferred Taxes Liabilities too high?
Insmed's current Current Deferred Taxes Liabilities is $0 Mil. Overall, Insmed has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's Current Deferred Taxes Liabilities compare to BNTX and INCY?
Insmed's Current Deferred Taxes Liabilities of $0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Biotechnology company?
A good Current Deferred Taxes Liabilities depends on the Biotechnology industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Insmed and its competitors. Insmed's current Current Deferred Taxes Liabilities is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (LTS:0JAV) is currently considered Possible Value Trap. The stock's GF Value™ is $211.50, compared to a current price of $125.81 — trading 40.5% below its estimated fair value. The current Current Deferred Taxes Liabilities is $0 Mil. Insmed's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Insmed (LTS:0JAV), the current Current Deferred Taxes Liabilities is $0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insmed (LTS:0JAV) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of $125.81 is trading 40.5% below its estimated GF Value™ of $211.50. GuruFocus considers Insmed to be Possible Value Trap.

Key valuation signals for LTS:0JAV:

  • Current Deferred Taxes Liabilities: $0 Mil
  • GF Value™: $211.50 vs. price of $125.81 (40.5% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the LTS:0JAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insmed Business Description

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
57GF Score

Get the complete analysis for LTS:0JAV

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$125.81
Price
$211.50
GF Value